Cereno Scientific – increased international activity and exposure15 October, 2019
Thrombosis is the most common cause of death the world over, whilst heart attack and stroke are the most common thrombosis-related complications. Furthermore, today’s thrombosis-preventative treatments increase the risk for serious bleeding. This has opened the door for brand new treatment concepts such as CS1, Cereno Scientific’s primary drug candidate that strengthens the body’s natural defences against thrombosis whilst reducing the risk of bleeding.
Read the full article on BioStock here.